SNS01-T: Phase Ib/IIa amended

Senesco said it amended an open-label, dose-escalation, U.S. Phase Ib/IIa trial of twice-weekly IV

Read the full 141 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE